-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Downgrades Keros Therapeutics to Neutral, Lowers Price Target to $18

Benzinga·06/10/2025 12:56:50
Listen to the news
B of A Securities analyst Jason Zemansky downgrades Keros Therapeutics (NASDAQ:KROS) from Buy to Neutral and lowers the price target from $32 to $18.